Preview a curated investor-scientist gathering debating which longevity research will attract capital and translate into clinical and commercial progress.
Key Takeaways
- Longevity biotech is moving from early promise toward clinical execution and commercialization
- Conference prioritizes matching rigorous geroscience with the capital needed for translation
- LIC combines scrutiny, debates, and a startup pitch program to connect founders with informed investors